The funding will support development for the company’s SB-1 Remedisc treatment, according to a March 28 news release. It is a seven-amino acid chain peptide and designed to decrease inflammation and maintain the structural integrity of the disc.
The funding was led by Viscogliosi Bros. Existing investors include Cercano Management and Pacira Biosciences.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
